Micromet, Inc.
http://www.micromet.de
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Micromet, Inc.
Editas’s EDIT-101 Faces Uncertainty As LCA10 Data Lack BRILLIANCE
Data showed efficacy limited to IVS26-mutant Leber congenital amaurosis 10, which affects only 300 patients in the US. The company is pausing enrollment as it seeks a partner.
ESMO: Relay’s RLY-4008 Shows High Response, Lower Toxicity In Cholangiocarcinoma
The new data bolster the company’s hypothesis that more specific targeting of FGFR2 can overcome the toxicity limitations of other FGFR inhibitors.
Zealand Nabs Novo Nordisk To Save Zegalogue Launch
US approval for its hypoglycemia injection Zegalogue last year has not been converted into commercial success. Zealand will be hoping that having diabetes giant Novo Nordisk onboard will put that right.
Saniona Seeks Partners To Secure Survival
CEO Thomas Feldthus's new broom is sweeping clean at Saniona with the closure of its US operations and an aim of exploiting the significant interest being shown across its pipeline programs.
Company Information
- Other Names / Subsidiaries
-
- CancerVax Corporation